Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(290)
•••
Comment by Moonshiner592on Mar 09, 2020 6:18pm
96 Views
Post# 30785675

RE:Waiting Game

RE:Waiting Game
HighSkies2019 wrote: Alot of mixed emotions by all I would say b4 9.30 bell ... and let's face it with no news release IIROC and Kly will be bombarded with overload of complaints demanding explanation ... hold tight and hope for the best ... glta


.. well .. it does say "pending news release" ... so to me ..there has to be something to be announced at tomorrow's open ... remember - they have to be coming into some $$ in order to get that recent acquisition - 

They may have stalled today (which is fantastic) due to the big crash with oil .. only time will tell though ...

Fingers crossed it's something we longs are much ... much waiting to see... especially seeing a day like today ... I have been trading for about 2 decades .. I've NEVER .. ever seen the index at minus 1660!! *** god almighty*** 

GLTA ... go KALY ....GO!!!!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities